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Summary CCN2 is one of the representative members of the CCN family, a group of proteins
that orchestrate the extracellular signaling network. As anticipated by the original name,
connective tissue growth factor, this molecule promotes the growth and development of
mesenchymal tissues, including bone and cartilage. Indeed, CCN2 is required for the proper
development of the orofacial region, which requirement is typically suggested by the frequent
emergence of cleft palate in CCN2-null mice. The significant contribution of CCN2 to mandibular
morphogenesis and tooth germ development has also been indicated. Of note, CCN2 functions not
only during development, but also later in life, as it is a critical promoter of physiological and
pathological tissue remodeling, the latter of which denotes fibrotic reconstruction of tissue. In
addition to its involvement in fibrotic disorders in a variety of organs, CCN2 has been also reported
to be a mediator of periodontal fibrosis caused by several factors including smoking. Based on
these cumulative findings, the utility of CCN2 to accelerate oral tissue regeneration by a
harmonized remodeling process is discussed herein, together with regulation of the gene
expression and molecular function of CCN2 as a therapeutic strategy against periodontal fibrosis.
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102 S. Kubota1. Introduction: the CCN family
Oral and maxillofacial tissues contain almost all types of the
hard tissues present in the human body. Not only the teeth,
which are found only in the oral cavity, but also bone and
cartilage are indispensable components of the basic struc-
ture of this part of the body section that best represents the
property of human being. Here, we should note that CCN2,
one of the classical members of the CCN family, is critically
involved in the development of these orofacial tissues as a
unique director that orchestrates the extracellular signal
traffic in the microenvironment.
The CCN family was founded by 3 classical members,
under the acronym of their original names [1]. The first
member, CCN1, was identified as a cysteine-rich protein
numbered 61 (Cyr61) induced immediately upon stimulation
by growth factors. CCN2 was initially discovered as connec-
tive tissue growth factor (CTGF) with mitogenic activity
toward fibroblasts. Thereafter, another relevant molecule
was found in a nephroblastoma overexpressed as a truncated
form, and was originally named NOV, and the CCN family was
born in 1993 [2]. It took another 5 years until the other
members finally joined to establish a family with 6 members
in mammals. Owing to the significant impact of a single
report describing all of the 3 additional members as Wnt-
inducible secreted proteins (WISP), these members have
been frequently referred to by this WISP terminology [1].
Furthermore, in addition to these popular names, a variety of
other names were given to most of the CCN family members,
which led to significant scientific confusion [1,3—5]. There-
fore, a unified nomenclature was proposed in 2003 with the
consent of major researchers on the CCN family [6]. There-
fore CCN2, rather than CTGF, is the name officially recom-
mended by the International CCN Society.
Structurally speaking, all CCN members are characterized
by a commonly conserved modular structure. With the only
exception being CCN5 with 3 modules, CCN family members
are composed of 4 distinct modules placed in tandem
[1,3,4,7—10]. Following the signal peptide for secretion,
insulin-like growth factor binding protein (IGFBP), von Will-
ebrand factor type C repeat (VWC), thrombospondin type 1
repeat (TSP1) and carboxy-terminal cystine knot (CT) mod-
ules are connected in this order. All of these modules are
characterized by conserved cysteine residues and are highly
interactive. This novel structure comprising ‘‘sticky’’ mod-
ules provides the molecular background for the multifunc-
tionality of the CCN family proteins. While each module itselfinteracts with multiple factors, the modules do not appear to
collaborate to construct a specific functional domain with a
higher-ordered structure [11]. Thus, these proteins should be
categorized to a novel group of proteins defined under a
paradigm distinct from that for regular signaling molecules.
In this context, CCN family proteins may be metaphorically
referred to as ‘‘4-handed conductors.’’ Orchestral conduc-
tors do not actually play musical instruments to make sounds.
Instead, they manipulate or direct all of the players around
them to manufacture an integrated world of music with a
variety of sound sections. Fortunately, the CCN family pro-
teins possess 4, or at least 3, hands to lead their colleagues in
the microenvironment to organize the tissue.
Among the 6 members, CCN2 has been standing out from
the others in terms of its biological significance. According to
the reports accumulated until today, critical involvement of
CCN2 in skull and tooth development, as well as bone regen-
eration is indicated [1,5], whereas no comparable informa-
tion is available regarding the other members. Moreover,
CCN2 is the only member that mediates fibrotic remodeling of
periodontal tissues. Here, the molecular behavior and func-
tion of CCN2 in orofacial tissues are comprehensively
described and discussed, based on such a scientific back-
ground. However, it should be also noted that contribution of
the other members therein still remains to be explored at
present.
2. CCN2: one of the founders with multiple
titles
CCN2 was originally purified and identified as a platelet
growth factor-associated protein [1]. Since this factor exerts
positive effects on the proliferation of a variety of the cells
[1,3,4,8—10], this original name has been, and even is still
being preferentially used among researchers in the field.
However, a vast number of the studies revealed quite diverse
functionality of CCN2, which obviously represents the prop-
erty of this molecule as a CCN family member, as summarized
in Table 1. Therefore, it is not surprising that nearly 10
different names have been assigned to this single molecule
during the progression of research on CCN2 [1,3—5].
Most critical biomolecules possess a dark side as well as a
bright side of their functions. In this point of view, CCN2 is a
typical double-edged sword in various microenvironments.
Indeed, CCN2 is involved in physiological events during the
development and growth of a variety of organ and tissues
[1,10], particularly of mesenchymal ones. Positive aspects of
Figure 1 Molecular action of a CCN family member, CCN2.
CCN2 displays multiple functions via interactions with multiple
molecular counterparts, using 4 modules represented by the
connected spheres in the center. Through the interaction with
ECM molecules, this factor integrates ECM with the cells by
acting as a matricellular protein. By interacting with several
growth factors, CCN2 either positively or negatively modulates
their activities. Finally, direct binding with cell-surface recep-
tors triggers cell adhesion, migration, and intracellular signal
emission to induce specific intracellular events. As a result, CCN2
manipulates a huge signaling network composed of numerous
biomolecules in the microenvironment.
Table 1 Diversity found in CCN2 terminology and function.
Proposed nomenclature
[1,5]
CTGF FISP12 Hcs24 ßIG-M2





Prolife rat ion Di fferentiat ion  De differentiat ion
Adhes ion  Migrat ion  ECM  pro duction   Apoptos is
Physiological roles
[5,14,75]






Fibrosis Liver Lung Heart Kidney
Skin Pancreas  Gingiva
Tumors Breast cancer Skin cancer Pancreatic cancer
Colonolec tal  ca nce r  Melanom a Chondrosarcoma
Oral cancer Bone metastasis
Others Inflammation Biliary atresia Nephropathy
Atherosclerosis Alzheimer's disease
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potential of this molecule to accelerate the regeneration of
damaged tissues, including bone and cartilage [12,13]. Of
note, even a cardioprotective effect of CCN2 against myo-
cardial ischemia-reperfusion injury was reported [14]. Most
relevant reports describe the positive effects of CCN2 on cell
growth and differentiation [9,10], save for one showing the
dedifferentiation of skeletal muscle cells induced by CCN2
[15]. Contrarily, it is also widely recognized that CCN2 is a
major mediator of fibrotic disorders and a critical determi-
nant of the phenotype of certain malignancies. Involvement
of CCN2 in fibrosis of multiple organs was described in a
number of reports [4,7,16], conferring the title of profibrotic
molecule on CCN2. As listed in Table 1, pathogenic involve-
ment of the CCN2 gene is frequently observed in a large
number of types of malignant tumors, including cancers that
originate in the epidermis [4,7,10,17]. These findings may
indicate the possible contribution of CCN2 to epidermal-
mesenchymal transition (EMT) events, because this factor
acts as a key player in mesenchymal tissue development.
However, the role of CCN2 in determining the malignant
phenotype is still controversial and complicated. It has been
solidly indicated that CCN2 promotes bone metastasis of
breast cancers [5,10], whereas its overexpression rather
shifts the phenotype of oral cancer cells toward a benign
one [18,19]. How can CCN2 action have such apparently
opposite outcomes?
As briefly stated in the previous section, the multiple
biological outcomes effected by CCN2 are conferred by
multiple interactions with a vast number of collaborative
molecules (Fig. 1). In fact, CCN2 is reported to interact with
multiple molecular counterparts from different categories
[7,10,20—23], which are summarized in Table 2. This inter-
action with a variety of collaborators enables CCN2 to
execute apparently contradictory missions, i.e., cell growth
and differentiation under the physiological state as well asmalignant transformation and benign conversion under the
pathological state. Additionally, direct activation of intra-
cellular signaling can be triggered through several cell-sur-
face receptors, such as integrins, LRP1, LRP6, and Trk A, to
which particular ligands other than CCN2 are already spe-
cified [7,10,23,24]. Surprisingly, the direct interaction
between the intracellular estrogen receptor and CCN2
and its functional significance have also been recently
Table 2 Molecular counterparts of CCN2.
Category Name Outcome of interaction
Cell surface molecules [10,25] Integrins FAK activation, cell adhesion, migration
LRPs Modulation of Wnt, ERK and PKC signalings
Trk A Initiation of multiple signal transduction
Enhancement of cytokine production
Membrane HSPG Cell adhesion, differentiation, proliferation
Growth factors [10,25] BMPs Modification of BMP signaling
TGF-ß Enhancement of TGF-ß signaling
FGF-2 Modulation of FGF signaling
VEGF Inhibition of VEGF function
ECM components [10,20,23] Fibronectin Cell adhesion
Aggrecan Enhancement of aggrecan production
Decorin Inhibition of CCN2 activity
Other [22] Estrogen receptor Suppression of transcriptional activation
Abbreviations: LRP, low density lipoprotein receptor-related protein; HSPG, heparan sulfate proteoglycan; BMP, bone morphogenetic
protein; FGF, fibroblast growth factor; VEGF, vascular endothelial growth factor.
104 S. Kubotasuggested [22]. As a result of these interactions, CCN2
appears not only to participate in the generation of orofacial
tissues during development, but also to promote remodeling
and regeneration thereafter.
3. Roles of CCN2 in orofacial tissue
development
3.1. Endochondral ossification
The human skull consists of a number of elements of a variety
of sizes and shapes. Upon delivery, the initial skull of a baby is
composed of more than 40 elements, which eventually fuse
into 22 bones to constitute the adult skull. Among them, the
major parts supporting the brain are formed through a
developmental pathway entitled endochondral ossification
[3,25].
Endochondral ossification is a sophisticated biological
process established during vertebrate evolution. In this
process, bones are primarily formed as cartilage anlagen
with comparable shapes. Along the course of development
and growth, cartilaginous tissue grows and is gradually
replaced with mineralized bone (Fig. 2A). During this pro-
cess, CCN2 is vigorously produced at the early hypertrophic
(prehypertrophic) stage and infiltrates the surrounding
extracellular matrix (ECM) toward target cells to accom-
plish multiple missions [3,25]. First, this molecule pro-
motes the proliferation and ECM deposition capability of
chondrocytes behind the producers. Second, it accumulates
in hypertrophic chondrocytes to accelerate hypertrophy
and apoptosis. Third, vascular invasion into the cartilage
is promoted by the angiogenic activity of CCN2. Fourth,
formation of osteoclasts/chondroclasts can be also pro-
moted by CCN2. Fifth and finally, bone formation by osteo-
blasts is enhanced by the same factor, as described in the
next subsection. These profound roles of CCN2 in endo-
chondral ossification are represented by the phenotype
observed in CCN2-null mice with retarded and abnormal
endochondral ossification characterized by impairment ofboth ECM production and vascular invasion at the growth
plate cartilage [26].
3.2. Intramembranous ossification
Since the cranium is basically a fossil-like structure evolved
from an ancient exoskeleton, a significant number of the
facial bone components follow a distinct process entitled
intramembranous ossification [27]. In this alternative path-
way of bone formation, mineralized bone is directly formed
by osteoblasts differentiated from mesenchymal stem cells,
without forming any intermediate cartilaginous tissue.
Recently, CCN2 was shown to be required for this bone-
forming process, as well as endochondral ossification in
mice. In normal osteoblasts isolated from the mouse cra-
nium, CCN2 was found to be expressed at early stages of their
differentiation [28]; and exogenous CCN2 strongly enhanced
the production of bone ECM components and matrix calci-
fication by osteoblasts [7,28,29]. Therefore, this molecule is
thought to act on osteoblasts in an autocrine manner to
support the efficient construction of the craniofacial bone
elements. Consistent with these in vitro findings, CCN2 null
mice display remarkably reduced levels of bone ECM produc-
tion and mineral deposition in the cranial elements. In vitro
analysis with CCN2 null osteoblasts further confirmed a
drastic reduction in osteogenic marker gene expression
and mineralization potential, which was efficiently compen-
sated by the addition of CCN2 protein [28]. It should be noted
that the CCN2 null mice suffer from cleft palate [26], again
supporting the biological significance of CCN2 in orofacial
bone development.
3.3. Articular and auricular cartilage formation/
maintenance
In contrast to the cartilage anlagen that disappear after
bone morphogenesis and growth, several types of cartilage
persist there to execute their proper biological missions.
Among these permanent cartilages, the most typical and
Figure 2 Production and roles of CCN2 in cartilage-directed
bone formation. CCN2 molecules are represented by marked
stars. (A) Those acting in endochondral ossification. In this
process, bones are initially formed as cartilage anlagen (upper
left) and follow the development and growth pathway towards
the completion of the adult form (upper right). Bone growth and
internal ossification are carried out at the growth plates (bot-
tom) located on the ossification centers (upper center). Resting
chondrocytes (RC) first proliferate (proliferative chondrocytes:
PC) and differentiate to support cartilage growth; and then these
cells produce abundant CCN2 at the prehypertrophic stage
(PHC). CCN2 infiltrates around and accumulates in the hypertro-
phic layer to enhance the activities of all of the cells involved.
Along with growth, the cartilage matrix and hypertrophic chon-
drocytes (HC) in the hypertrophic zone are simultaneously
replaced with bone tissue by chondroclasts (Cc) and osteoblasts
(Ob), along with vascular invasion by endothelial cells (VE). (B)
Comparable events occurring at the junction of Meckel’s carti-
lage and ossifying region at the late stage of development. Since
Meckel’s cartilage does not grow to become mandibular bone in
mammals, the polarized growth plate structure is not evident;
however, chondrocytes undergo hypertrophic-like differentia-
tion, while producing CCN2 along the ossification site facing
the cartilage. Mandibular bone is formed attached to the ‘‘hy-
pertrophic’’ layer of Meckel’s cartilage with marginal bone
matrix invasion into the cartilage. CCN2 can be found also inside
the cartilage, suggesting its role in cartilage development.
CCN2 in orofacial tissue development and remodeling 105ubiquitous one is the articular cartilage in joints. In the oral
region, we find the temporomandibular joints (TMJs) as the
only joints, which collaborate together to realize the com-
plex movement needed for mastication, pronunciation, andother oral activities. Although the development and growth
scenario of the cartilage of the mandibular condyle are not
exactly the same as those of long bones [30], the roles and
biological significance of CCN2 in both tissues are compar-
able. Thus, the findings described here on the CCN2 function
in relation to articular cartilage ought to apply also to the
TMJ cartilage.
Articular cartilage develops from the epiphysis of the
primordium, in which some of the chondrocytes are engaged
in constructing permanent cartilage, while the others
undergo ossification around the secondary ossification cen-
ters. CCN2 is believed to support both types of differentiation
process; whereas the fate of chondrocytes towards these 2
distinct missions is determined by another CCN family mem-
ber, CCN3 [31]. After the development of articular cartilage,
CCN2 gene expression in articular chondrocytes is not evi-
dently seen in vivo. Nevertheless, in vitro analyses showed
that the addition of CCN2 to cultures of articular chondro-
cytes isolated from adult cartilage promotes both prolifera-
tion and maturation of these cells [3,7]. Importantly, albeit
CCN2 promotes the calcification of chondrocytes following
the endochondral ossification pathway, it never promotes the
calcification of articular chondrocytes leading to osteophyte
formation in osteoarthritis (OA). These findings indicate a
significant role of CCN2 in the developmental processes of
articular cartilage as well.
In addition to TMJ cartilage, our cranium possesses other
cartilaginous components, which are of functional and par-
ticularly of esthetical importance. One of them is the auri-
cular cartilage constructing the ear. Concerning the role of
CCN2 in this tissue, a single report has described the effect of
CCN2 on it [32]. According to this study, CCN2 promotes the
proliferation and production of elastin fibers, which is one of
the typical characteristics of elastic cartilage cells. Of note,
as in the case of articular chondrocytes, CCN2 does not
induce either apoptosis or calcification in auricular chondro-
cytes. Therefore, CCN2 may also be a promoter of auricular
cartilage development.
3.4. CCN2 in Meckel’s cartilage
Mandibular bone is recognized to be formed by intramem-
branous ossification. However in this process, Meckel’s
cartilage, which is a transient cartilage developing from
the first branchial neural crest cells, mainly serves as a
template of mandibular bone and contributes also as a
limited part after ossification [33]. During mandibular
development, CCN2 gene expression is observed to occur
in 2 distinct stages [34]. At the first stage, strong CCN2
gene expression is detected throughout the Meckel’s car-
tilage primordium before the cartilaginous structure
becomes evident, suggesting the contribution of CCN2 to
Meckel’s cartilage formation itself. Indeed, CCN2 acceler-
ates the adhesion and aggregation of the first branchial
arch cells. Another study, one using TGF-b receptor 2
knockout mice, indicated that CCN2 is a major signaling
molecule downstream of the TGF-b signal, which supports
the chondrocyte proliferation required for the formation of
Meckel’s cartilage [35].
After the initial formation of Meckel’s cartilage, CCN2
production is then silenced in the chondrocytes. Then, it
Figure 3 Expression of the CCN2 gene during tooth germ
development. Dental epithelium and mesenchyme are repre-
sented by solid objects and stippled background, respectively.
Zones showing CCN2 gene expression are illustrated by shadows
with arrowheads, according to the findings presented by Shimo
et al. [41]. The area with a wavy pattern in the crown stage
denotes the nascent tooth enamel.
106 S. Kubotarecurs upon the hypertrophic-like differentiation of these
cells [34]. Interestingly, along the emerging hypertrophic
chondrocyte-like cells, ossification is initiated surrounding
Meckel’s cartilage, which is reminiscent of the events occur-
ring at the cartilage-bone boundary of the growth plate
during endochondral ossification (Fig. 2B). This observation
suggests a critical role of CCN2 as a signaling molecule that is
released from Meckel’s cartilage and recruits the osteoblasts
from the developing mesenchyme. One may consider this
event distinct from endochondral ossification, since ossifica-
tion proceeds not from the inside, but from the outside of the
cartilage. Nevertheless, the fundamental role of CCN2 as a
messenger from chondrocytes to osteoblasts to guide the
ossification is quite similar, well representing the functional
property of this molecule.
3.5. CCN2 and tooth development
As observed in a number of organogenic processes including
heart, lung, and kidney development, odontogenesis fol-
lows multiple steps, in which epithelial—mesenchymal
interaction is critically required [36]. After the formation
of dental lamina, it penetrates into the underlying oral
mesenchyme to co-manufacture a tooth bud. The tooth
bud then develops into the enamel organ, dental papilla,
and dental follicle at the cap stage, and tooth morphogen-
esis is conducted during the following bell stage. At the final
crown stage, cells localized in contact at the boundary
between the enamel organ and dental papilla rapidly dif-
ferentiate into ameloblasts and odontoblasts. Following the
initiation of dentin production by odonotoblasts, deposition
of enamel matrix is started by ameloblasts to accomplish the
tooth construction.
In this developmental pathway, CCN2 is recognized to play
a significant role as well. Throughout odontogenesis, CCN2 is
produced under a distinct temporospatial regulation in mur-
ine tooth germs [1,37]. Expression of the CCN2 gene begins
immediately after the formation of dental lamina. At the cap
stage, prominent CCN2 expression is restricted to the enamel
knot located at the very center of the enamel organ-dental
papilla attachment (Fig. 3). CCN2 gene expression persists in
the epithelial and mesenchymal cells along the epithelial—
mesenchymal boundary of the tooth germs throughout the
bell stage. However interestingly, the expression is shut down
among ameloblasts at the crown stage. Detectable levels of
CCN2 continue to be present in the dental follicle and outer
dental epithelium and even in the involuting dental lamina.
It should be particularly noted that the induction of CCN2
gene expression in the dental epithelium is dependent on the
signal provided by the direct contact between it and the
dental mesenchyme. Nevertheless, the molecules responsi-
ble for this CCN2 induction have not been specified, though
TGF-b and BMP-2 are capable of inducing CCN2 production in
the dental epithelium [37]. However, another report suggests
that signals induced by CCN2 during odontogenesis may be
independent of TGF-b signalings [38].
In any case, studies with recombinant CCN2 and its
neutralizing antibody indicate that CCN2 promotes not only
the proliferation but also the differentiation of both epithe-
lium and mesenchymal cells, which together form the tooth,
thus indicating its solid contribution to odontogenesis.Nevertheless, a recent report described that tooth germs
develop normally even in CCN2-null mice [38]. These appar-
ently contradictory data suggest the functional redundancy
of the CCN family members. Indeed, both CCN1 and CCN2
have been reported to exert the same effects on the same
cells, and both are strongly induced by the same factors [39].
Therefore, it may be assumed that another CCN family
member may be able to play a compensational role in
odontogenesis in the absence of CCN2.
4. CCN2 as a mediator of tissue remodeling
4.1. CCN2 as a single coupling factor that
coordinates efficient bone remodeling
As widely recognized, bone remodeling is continuously
performed under the collaboration of osteoblasts and
Figure 4 CCN2 as a single coupling factor for bone remodeling.
In bone tissues, CCN2 is produced by immature osteoblasts and
mononucleate osteoclast precursors, and initially stored in the
ECM. CCN2 (a marked star) in the ECM acts on both cell types to
promote their maturation for the coupled resorption and syn-
thesis in a sustainable manner through matricrine actions. Ob,
osteoblast; Oc, osteoclast.
CCN2 in orofacial tissue development and remodeling 107osteoclasts, in order to maintain the integrity of bone tissue
and calcium homeostasis of the whole body. Mineralized
bone is decalcified and its matrix proteins are degraded by
osteoclasts. In parallel with bone resorption, nascent bone
is produced by osteoblasts to reconstruct the tissue. Not
only systemic factors, but also local factors and cell-surface
molecules tightly regulate the behavior of osteoblasts and
osteoclasts toward each other. These molecules that med-
iate the direct interaction between these cells are gener-
ally designated as coupling factors. The best known pair of
coupling factors is the receptor activator of NF-kB (RANK)
on osteoclast progenitors and the RANK ligand (RANKL) on
osteoblasts [40]. Additionally, another pair of cell-surface
molecules was more recently nominated as novel coupling
factors of bone remodeling, i.e., the ephrin B2 ligand on
osteoclasts and the EphB4 receptor tyrosine kinase on
osteoblasts [41]. Of interest, ephrin B2 has also been shown
to be produced by periodontal ligament cells in a strain-
dependent manner, indicating its involvement in bone
remodeling upon orthodontic tooth movement [42].
Here, another mode of coupling between these cells is
proposed (Fig. 4). As described in a previous section, CCN2 is
produced by osteoblasts at early stages of differentiation and
promotes their proliferation and osteoblastic differentiation
[28]. Moreover, our recent study revealed that the same
CCN2 molecule enhances osteoclastogenesis via interaction
with dendritic cell-specific transmembrane protein (DC-
STAMP), which is a cell-surface molecule playing a role in
the cell fusion events that occur upon the maturation of
osteoclasts [43]. In that report, the production of CCN2 by
osteoclast progenitors was confirmed as well. As such, this
single molecule, CCN2, is indeed coupling osteoblasts and
osteoclasts and modulating the action of both cells; and thus
it deserves the title of single coupling factor of bone remo-
deling. Since CCN2 acts on both types of the cells positively,
this factor may be coordinating efficient and balanced bone
remodeling. This functional property of CCN2 is well demon-
strated by the regenerative effect of CCN2 on bone defects
[13]. The fact that mechanical stimuli induce CCN2 produc-
tion by osteocytes also indicates the property of CCN2 as a
coordinator of bone remodeling [44].4.2. Possible cartilage remodeling by CCN2 for
maintaining tissue integrity
Despite that cartilage evolved from a prototypic endoskele-
ton that supported the body, biological missions assigned to
the present permanent cartilage in the human body are quite
different from those of bone. Since uncalcified cartilage does
not serve as a storage depot for calcium and phosphate, it is
not necessary for cartilage to be continuously remodeled to
support calcium homeostasis. Nevertheless, instead of being
major skeletal components of the face, our cartilage plays a
critical role by enabling flexible movement of our jaws,
taking advantage of its elasticity and stiffness.
The major role of articular cartilage is to soften the
friction and absorb the pressure between the bones upon
movement; hence, it is constantly subject to mechanical
stress load and minor injury. Therefore, another mode of
tissue remodeling does occur in response to these stimuli, in
order to maintain the physical properties of articular carti-
lage. In this context, it is important to mention that CCN2
protein is induced in chondrocytes upon mechanical stress
load [45]. Furthermore, although CCN2 production by articu-
lar chondrocytes is normally under the detection threshold,
marked CCN2 produced from clustering chondrocytes is
observed upon the development of OA [46]. This CCN2
induction seems to be mediated in part by macrophage-
colony stimulating factor (M-CSF), also suggesting an unex-
pected anabolic functional aspect of this molecule in carti-
lage [47]. According to the fact that CCN2 promotes the
proliferation and ECM-molecule production of articular
chondrocytes in vitro, it is reasonable to consider that
CCN2 is induced to reconstruct the damaged articular car-
tilage. Conversely, cartilaginous ECM degradation is directly
carried out by proteases, such as MMPs and ADAM-TS5. It is
known that mechanical injury induces the production of
FGF-2 in articular cartilage, which subsequently provokes
the production of a number of MMPs including MMP-13. It is
important to note that a recent study revealed the mole-
cular interplay between CCN2 and FGF-2 in cartilage [48].
Thus, CCN2 is believed to reorganize the articular cartilage
architecture against external stress to maintain its integrity
under collaboration with other signaling molecules such as
FGF-2.
4.3. Tissue remodeling toward orofacial wound
healing and fibrosis by CCN2
Upon oral tissue injury, the wounded areas are primarily
filled with blood clot with polymerized fibrin molecules
formed through the activation of platelets and the coagula-
tion cascade. Subsequently, fibroblasts migrate therein and
occasionally differentiate into myofibroblasts to produce
fibrotic ECM molecules such as type I collagen. This process
may be followed by the contraction of the wounded area by
a-smooth muscle actin-positive myofibroblasts. During this
tissue regeneration process, CCN2 is supplied by multiple
sources and plays central roles in the regeneration.
Although CCN2 is abundantly encapsulated in platelets
and released upon activation of them [25], it is also endo-
genously produced by the cells around the injured area. In
fact, strong expression of the CCN2 gene is observed in the
108 S. Kubotatooth extraction sockets [49], as well as in the wounded
dermal tissue [50]. Data obtained in vitro showed that CCN2
enhances the synthesis of type I collagen in fibroblasts and
periodontal ligament cells [51,52], further supporting this
notion.
Tissue fibrosis, which is characterized by the abnormal
accumulation of a vast amount of fibrous ECM and functional
deficiency, can be regarded as an unsuccessful outcome of
continuous tissue remodeling toward reconstruction. Con-
sistently, CCN2 is known to be a key molecule that develops
fibrotic disorders in a variety of organs. The target organs in
humans include most tissues and organs including liver,
kidney, lungs, pancreas, and heart as well as orofacial
tissues, save for neuronal and genital ones [1,4,7]. Over
the past 10 years, CCN2 has been attracting the interest of
dermatologists, since it mediates the pathological changes
observed in progressive systemic sclerosis or scleroderma
[4,53,54]. In the oral cavity, the most prominent findings
indicating the relevance of the CCN2 molecule to fibrotic
disorders have come from investigations on drug-induced
gingival overgrowth [55,56]. This symptom is characterized
by an overwhelming growth of gingiva composed of a highly
fibrous tissue with elevated CCN2 production, which is
induced by an anti-convulsant, phenytoin, or a calcium-
channel blocker, nifedipine. Similar changes may be induced
under certain oral conditions; for example, occlusal dys-
function and mechanical tension on individual cells have
been implicated in the induction of CCN2 in gingiva [57,58].
Mechanical stress load-induced CCN2 would supposedly
mediate periodontal tissue remodeling both physiologically
and pathologically.
Apart from these factors, there is another major risk
factor that causes periodontal fibrosis. Clinically, gingival
fibrosis has been frequently observed among smokers,
although the mechanism of the onset has not yet been
clarified. However, it is now clear from a recent study that
nicotine in the smoke is the major agent that induces period-
ontal fibrosis [59]. In cultures of normal human gingival
fibroblasts and periodontal ligament cells, nicotine promotes
CCN2 production and type I collagen deposition that can be
neutralized by anti-CCN2 antibody. It is already known that
these periodontal cells produce CCN2 in response to TGF-b by
transcriptional activation of the CCN2 gene [60,61], whereas
no transcriptional activation is observed upon nicotine treat-
ment. Thus, a TGF-b-independent, post-transcriptional reg-
ulation is driving the expression of CCN2 mRNA in this event
occurring in a smoker’s oral cavity.
Since plaque control and other management of period-
ontal disease under a fibrous gum are difficult, the period-
ontal disease that occurs in these patients is generally
resistant to dental therapeutics. Therefore, molecular ther-
apy targeting CCN2 can be considered for the gingival fibrosis
mentioned above, even though quitting smoking is the best
choice for the last case. Finally, CCN2 is also known to play a
significant role in the maintenance of the integrity of oral
mucosa other than the gingiva. According to a recent report,
CCN2 is suggested to be responsible for the submucous
fibrosis induced by arecoline, an active ingredient of Areca
nuts traditionally consumed in certain Asian countries, on the
buccal oral mucosa [62]. Both nicotine and arecoline are
known as carcinogens, supporting the findings that CCN2 is
involved in malignant tumors of various organs as well.5. CCN2 as a therapeutic tool or target in
dental medicine
5.1. Cartilage regeneration by CCN2
Flexible movement of synovial joints including the TMJ highly
depends on the smooth, elastic, and lubricated surface
properties of articular cartilage. Therefore, loss of integrity
of articular cartilage, which is usually caused by repetitive
mechanical stress load, results in OA with severe locomotive
dysfunction. Because of the complicated movement required
for their multiple activities, TMJ joints are highly susceptible
to OA-like damage. Indeed, TMJ dysfunction has been noted
as a common and major clinical complication in the area of
clinical dentistry for a long time, even before OA was recog-
nized as a serious issue in orthopedics.
OA is one of the major complications frequently found in
aged persons in advanced countries [63]. Since OA greatly
affects the quality of life of these patients, exploring a novel
and fundamental therapeutic strategy is earnestly desired by
societies worldwide. In OA cartilage, the articular cartilage
has biologically and physically disintegrated mainly due to
long-term mechanical overload, in spite of the attempt of
articular chondrocytes to proliferate and to produce CCN2 for
repair [46]. Therefore, it would be quite reasonable to use
CCN2 as a supplement to overcome the damage to the
cartilage in OA. Indeed, exogenous application of CCN2
remarkably ameliorates the OA-like changes in an experi-
mental rat model [12], and forced expression of CCN2 in
cartilage protects the articular cartilage from OA-like
damage in mice [64]. These findings indicate a solid utility
of CCN2 for the treatment of OA and TMJ dysfunction (Fig. 5).
The regeneration potential of CCN2 is more clearly seen
from the results of experiments with another rat model. For
obtaining severest damage to articular cartilage, Nishida
et al. prepared rats with a full-thickness defect in their knee
cartilage [12]. Exogenous application of CCN2 into the car-
tilage defect, in combination with gelatin hydrogel for gra-
dual release, efficiently regenerated articular cartilage
therein, without causing overgrowth.
As stated in a previous section, CCN2 is also capable of
enhancing the regeneration of auricular cartilage [32].
Indeed, the application of CCN2 onto the cultured auricular
chondrocyte pellets enhances their growth in vivo as sub-
cutaneous explants. Although no reports have described the
regeneration of damaged pinna in vivo, CCN2 may be useful
in esthetic reconstruction of ears, if an appropriate drug
delivery system can be established as actually done in the
case of articular cartilage.
5.2. Bone regeneration by CCN2
In addition to the in vitro findings that CCN2 promotes the
proliferation and differentiation of osteoblasts, it was also
shown that CCN2 is produced at the site of regeneration after
a bone fracture [3]. Since the endochondral ossification-like
process recurs during the repair of a bone fracture, it may be
supposed that a sustainable supply of CCN2 is made possible
from platelets for immediate discharge and from prehyper-
trophic chondrocytes for delayed production after differen-
tiation. By mimicking this process, we are able to accelerate
CCN2 in orofacial tissue development and remodeling 109the regeneration of intractable bone defects. In a rat model,
application of CCN2 adsorbed onto gelatin hydrogel for dur-
able and gradual release efficiently accelerated the regen-
eration of intractable bone defects [13]. This is not of a great
impact per se; for other factors, such as BMP-2 and FGF-2,
have been indicated to be useful in promoting bone repair.
However, CCN2 has a precious advantage that is not found in
the case of these other bone-generating factors. In concor-
dance with the effect on damaged articular cartilage, CCN2Figure 5 Experimental prevention and treatment of OA with CCN
minimal degradation and balanced synthesis of the ECM to maintain th
(marked stars) stored therein (upper left panel). Mechanical or anothe
in white) also harms the matricrine retention of CCN2 as well as the
proliferate, forming clusters, and produce ECM (‘‘ECM’’ in black) com
quantity for regeneration of a duly organized ECM (upper right panel)
chondrocytes are ready to produce sufficient amounts of ECM mol
extensive damage (lower left panel). Even after the onset of OA, exte
matricrine stimulation by CCN2, resulting in the efficient assistance of
tissue. Dotted, solid, and open arrows denote molecule production
respectively.promotes the bone regeneration up to the exactly desired
level without inducing any overgrowth. In these cases, the
boundary of the original cortical tissue and the regenerated
one at the defect site is almost invisible by histological
observation [13]. The property of CCN2 to enhance the
healing potential of bone tissue in a harmonized manner is
of course ascribable to the molecular action of this protein as
a CCN family member. In clinical dentistry, alveolar bone
regeneration is a critical issue for the efficient support of2. Under normal conditions, adequate mechanical stress causes
e integrity of articular cartilage, which is supported by the CCN2
r extensive stress that induces massive ECM degradation (‘‘ECM’’
 physical properties of the cartilage. In response, chondrocytes
ponents and CCN2, which, however, end up being in insufficient
. In the presence of excessive CCN2 storage prepared in advance,
ecules to maintain the articular cartilage, even when it incurs
rnal and durable administration of CCN2 compensates the loss of
 articular chondrocytes to regenerate the disintegrated cartilage
 by, effect on, and proliferation of the articular chondrocytes,
110 S. Kubotadentures and stable fixation of dental implants for rigid
prosthesis. With BMP-2, for example, nowadays it is not
difficult to manufacture bone on the alveolar arch or at
the bottom of a sinus. Nevertheless, clinicians sometimes
face difficulty in the maintenance of the added bone against
subsequent resorption [65]. Considering its molecular nat-
ure, CCN2 may be more effective in keeping the engineered
bone in a desired form as a coordinator of bone remodeling.
5.3. Regulation of periodontal fibrosis via CCN2
Since CCN2 is a central mediator of fibrotic disorders, ther-
apeutic approach targeting CCN2 in controlling fibrosis in
every relevant organ ought to be explored in the future. In
the tissues present deep inside of the body, such as the heart,
kidneys and liver, a highly sophisticated drug delivery system
is indispensable to specifically target CCN2 in these organs
with agents that regulate its gene expression or modify its
molecular behavior. In contrast, the oral cavity and skin are
relatively easy to access without specific device for targeted
delivery. Therefore, the anti-CCN2 strategy against skin
dermal and gingival fibrosis is currently actively explored.
Molecular therapy targeting CCN2 is being developed
against drug-induced gingival fibrosis, since removal of etio-
logical factors is difficult in those cases [56]. A recent report
has indicated that activation of Smad7, a repressive mediator
of intracellular signal transduction, in gingival fibroblasts is
effective in preventing the CCN2 induction and fibroblast/
myofibroblast transition that cause gingival fibrosis [66].Figure 6 Regulation of the CCN2 gene and possible strategies for its
gene are shown in ellipses, whereas key factors for anti-CCN2 strateg
regulations represent direct and indirect effects of the correspondin
are illustrated, respectively above and below the illustrated CCN2
promoter, whereas lines indicate introns in the gene structure. T
pathways for CCN2 transcriptional activation as well as indirect indu
open reading frame (ORF) are also specified by solid boxes, whereas
representing the CCN2 gene and its mRNA. Other abbreviations: GAPHowever, selective activation of Smad7 inside the cells by
an extracellular approach appears difficult at present.
Another report has described that nifedipine-induced gingi-
val fibrosis that is mediated by CCN2 in concert with androgen
receptors can be inhibited by flutamide, a non-steroidal
receptor antagonist of androgens [67]. Regulation of CCN2
gene expression by direct administration of antisense oligo-
nucleotides is being attempted as well in vivo. According to a
recent study, injection of an anti-CCN2 modified oligonucleo-
tide into skin wounds represses scar formation without
affecting the proper wound healing process [68]. As such,
development of novel strategies to down-regulate CCN2 is
desired and is actually underway to control gingival fibrosis.
6. Conclusions for the future
According to the scientific evidence that has accumulated to
date, it is obvious that CCN2 plays a key role in the devel-
opment of orofacial tissues. Consistent with this notion, the
medical utility of CCN2 in regenerating cartilage, bone, and
other connective tissues has been established. Moreover, the
functional property of CCN2 as a critical mediator of fibro-
genesis is expected to provide a clue for the development of
anti-fibrotic therapeutics targeting this molecule. However,
one should carefully consider the novel molecular action and
multiple functionality of CCN2 in exploring this anti-CCN2
strategy in the future.
As explained in this article, CCN2 function is exerted by
the molecular interaction with a huge number of molecules therapeutic control. Factors affecting the expression of the CCN2
ies are marked by rectangles. Solid and dotted arrows indicating
g molecules. Transcriptional and post-transcriptional regulations
 gene structure. Thick and thin boxes indicate exons and the
GF-b utilizes both Smad- and Rac1/cdc42-mediated signaling
ction through endothelin-1 (ET-1). Coding exons comprising the
 untranslated regions (UTRs) are in open boxes in the structures
DH, glyceraldehyde 3-dehydrogenase; NPM, nucleophosmin/B23.
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control the molecular action of CCN2. For instance, devel-
opment of an antibody or an antagonist to inhibit all of the
functions of CCN2 is quite difficult, since diverse functions
are mediated by multiple interactions via multiple inter-
faces. Extensive investigation on the structural and func-
tional relationship is required and may be expected to
overcome this difficulty.
The other strategy to interfere with CCN2 function is to
regulate the CCN2 gene expression itself. In this point of view,
characterization of the CCN2 gene expression is of critical
importance (Fig. 6). Fortunately, a number of studies have
already uncovered the regulatory machinery of the CCN2 gene.
Every gene is controlled at transcriptional and post-transcrip-
tional stages during gene expression. Recently, TGF-b, the
best-known transcriptional stimulator of CCN2 gene expres-
sion, was shown to activate CCN2 transcription in human
gingival fibroblasts via Rac1/cdc42 small GTPase, as well as
via Smad and JNK intracellular messengers [60]. Notably,
statins inhibiting the formation of mevalonate, which is
required for cholesterol synthesis and the formation of active
Rac1/cdc42 molecules, were shown to inhibit the TGF-b-
induction of CCN2 gene expression [60]. Endothelin 1, which
is another inducer of CCN2 and may indirectly contribute to the
TGF-b-induced CCN2 gene transcription, can be another target
to regulate the local quantity of CCN2 [8,25]. MMP-3, an ECM-
degrading enzyme, was also found as a novel target to regulate
CCN2 gene expression; for this enzyme is taken up by cells and
directly binds to and controls the transcription of the CCN2
gene [69]. Also at post-transcriptional stages, several proteins
and noncoding RNAs are known to repress CCN2 gene expres-
sion, either by accelerating the degradation or repressing the
translation of the CCN2 mRNA [70,71]. Nucleophosmin/B23, a
histone chaperone shuttling between the nucleus and cyto-
plasm, was unexpectedly found to interact with and degrade
CCN2 mRNA in chicken chondrocytes [71]. Several miRNAs have
also been identified as post-transcriptional repressors of the
CCN2 gene [72,73]. Especially, these small RNAs and related
molecules can be promising agents to specifically repress the
CCN2 gene expression in the oral mucosa. Since endogenous
miRNA can be released from cells, it is expected that such small
RNAs would be incorporated through endocytotic pathways to
act against the CCN2 mRNA in the cytoplasm. Intracellular
delivery of small RNAs into the cells in deep zones of the skin
could possibly be mediated by a specific paste that was
designed for nucleic acid delivery [74]. Further advances in
drug delivery system and gene regulation research are
expected to provide a novel strategy for CCN2 gene silencing
to control the fibrosis of the gingiva and other relevant tissues.
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